A single company will supply reagents for a common cancer test for another year

The US government awarded a $1.4 million contract to Roche Diagnostics for Ventana reagents. These reagents are used in tests that detect specific proteins in tissue samples, often for cancer diagnosis.

This contract ensures a continued supply of critical diagnostic materials for government-funded healthcare facilities. It means that a specific type of cancer testing, which relies on these reagents, will remain available without interruption. For patients, it means consistent access to a diagnostic tool that helps determine treatment paths.